28.01.2021 • News

Polynt-Reichhold Up for Sale

The private equity owners of Polynt-Reichhold are seeking a sale of the specialty chemicals company, according to Reuters. Sources told the news agency that the value of any deal would likely be about €2.5 billion. An agreement is expected in the second quarter of this year.

Polynt-Reichhold was formed in 2017 from merging Polynt, owned by Italian buyout fund Investindustrial, with Reichhold, owned by US asset management firm Black Diamond Capital Management. The composites and resins producer has 40 manufacturing facilities worldwide and annual revenues of about €2 billion. It has three regional headquarters in located in Scanzorosciate, Italy (Polynt’s historical HQ); Carpentersville, Illinois, USA and Changzhou, China. 

Investindustrial is said to have picked Morgan Stanley to work on the sale, with the process due to start in the coming weeks. Reuters quoted an anonymous source as saying that the sale is going to “draw interest not just from industry names but private equity with the know-how and skills like Cinven or Apollo.”

Last September, Investindustrial and Black Diamond agreed to buy Hexion’s phenolic specialty resin, hexamine and European forest products resins businesses for about $425 million. The deal is due to close during the current quarter.

Author: Elaine Burridge, Freelance Journalist

The private equity owners of Polynt-Reichhold are seeking a sale of the...
The private equity owners of Polynt-Reichhold are seeking a sale of the specialty chemicals company, according to Reuters news agency. Sources said the value of any deal will likely be about €2.5 billion. An agreement is expected in the second quarter of this year. (c) Miguel Á.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.